Approvals in 2016: cost-benefit challenges of new anticancer agents
Ces articles analysent le rapport coût-efficacité des inhibiteurs de points de contrôle immunitaire, notamment les anticorps anti PD-1 et anti PD-L1, approuvés par la FDA en 2015 et 2016 dans le traitement des cancers
In 2016, four new anticancer drugs were approved by the FDA, and a further 12 existing agents were approved for 14 additional indications. Each one of these drugs is associated with important clinical benefits, but at an average monthly cost of ~US$9,000. Here, I discuss the cost–benefit considerations related to these treatments and contemplate future economic prospects.